- Alpine Immune Sciences Inc ALPN has voluntarily terminated enrollment in both clinical studies involving davoceticept (ALPN-202), an investigational CD28 costimulator, and a dual checkpoint inhibitor.
- The company has stopped enrollment in the NEON-1 study of davoceticept as monotherapy and the NEON-2 study of davoceticept in combination with pembrolizumab.
- Following these decisions, the company plans to focus its development resources primarily on ALPN-303 for multiple autoantibody-related inflammatory diseases and acazicolcept in development for systemic lupus erythematosus (SLE) in collaboration with AbbVie Inc ABBV.
- The decision to terminate enrollment in the davoceticept studies was made after the company was notified of a second death in the NEON-2 study, attributed to cardiogenic shock.
- The participant, who had metastatic colorectal cancer previously treated with colectomy and multiple prior systemic chemotherapies, had received a single dose of davoceticept and pembrolizumab.
- NEON-2 had previously been subject to a partial clinical hold due to a death attributed to cardiogenic shock.
- The FDA removed the clinical in May after reviewing davoceticept's safety database, revised investigator brochure, and the study protocol.
- The company is conducting an ongoing, comprehensive assessment of all NEON study participants.
- Price Action: ALPN shares are down 7.93% at $5.28 on the last check Monday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.